How to reduce suffering in children with advanced cancer remains an ongoing but urgent question. A Mass General Brigham-led study examined whether systematically surveying children with advanced cancer… read more.
NICE (UK): Avelumab plus axitinib can be used as an option for untreated advanced renal cell carcinoma (RCC) in adults, only if: i) they have a favourable-risk status,… read more.
People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A… read more.
Gilead Sciences Inc. announced Trodelvy (sacituzumab govitecan-hziy) has now been added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative… read more.
A new AI-powered model has been shown to advance treatment planning for spinal metastasis by calculating patients’ chances of survival. Doctors can then make informed decisions about, for… read more.
The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased… read more.
Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for… read more.
Researchers report that elevated lifetime alcohol consumption is associated with a higher risk of colorectal cancer, and that quitting heavy drinking might lower the subsequent risk. The findings… read more.
HutchMed highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (Orpathys) and osimertinib (Tagrisso )… read more.
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood that a… read more.
Caris Life Sciences announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. In… read more.
Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
